| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers D > Headlines for DSM Biologics > News item |
Invitrogen is first licensing partner for Crucell, DSM Biologics PER.C6 vendor network
By E. Janene Geiss
Philadelphia, July 10 - Crucell NV and technology partner DSM Biologics announced Monday that Invitrogen, a leading life sciences products and services provider, will become the first company to enter the partnership's PER.C6 licensing business vendor network for monoclonal antibodies and recombinant proteins.
Through its PD-Direct services, Invitrogen has extensive experience with the PER.C6 technology and will offer PER.C6 licensees the benefit of expertise developed as a leader in clone generation services, according to a company news release.
Invitrogen said it will continue to develop and optimize clone generation solutions specifically tailored to the PER.C6 human cell line.
The vendor network was created to develop and provide high-quality biotechnology tools and services specifically tailored to PER.C6, officials said.
It will consist of carefully selected leading tool and service providers offering, for example, PER.C6 clone generation programs, medium, bioreactor and other production equipment and devices, and process development services.
Vendors will ensure ongoing innovation of unique processes and products that enhance the performance of the PER.C6 technology platform, officials said.
Furthermore, they will use their marketing and sales efforts to offer PER.C6-related goods and services, thereby increasing the exposure of the PER.C6 brand worldwide.
Crucell is a biotechnology company based in Leiden, The Netherlands.
DSM Biologics, a business unit of Parsippany, N.J.-based DSM Pharmaceutical Products, provides manufacturing technology and services to the biopharmaceutical industry.
Invitrogen, based in Carlsbad, Calif., provides products and services that support academic and government research institutions and pharmaceutical and biotech companies.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.